2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethyl prop-2-yn-1-ylcarbamate | 945864-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethyl prop-2-yn-1-ylcarbamate
• 英文别名: 2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethyl N-prop-2-ynylcarbamate
• CAS: 945864-44-8
• 化学式: C₁₂H₁₄N₂O₅
• 分子量: 266.254
• InChiKey: YMVPJLLKFQQYAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethyl prop-2-yn-1-ylcarbamate 、 在 三氟乙酸 、 1,10-菲罗啉 、 copper(II) sulfate 、 sodium ascorbate 作用下， 以 氯仿 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 4.5h， 生成 [(1S)-1-(chloromethyl)-3-[6-[(4-hydroxybenzoyl)amino]imidazo[1,2-a]pyridine-2-carbonyl]-9-methyl-1,2-dihydrobenzo[e]indol-5-yl] N-[1-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[2-[2-[4-[[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxycarbonylamino]methyl]triazol-1-yl]ethoxy]ethoxycarbonylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methoxycarbonyl-methylamino]-2-methylpropan-2-yl]-N-methylcarbamate
  参考文献：
  名称：

  [EN] NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS
  [FR] NOUVEAUX CONJUGUÉS D'ANALOGUES DE CC-1065 ET LINKERS BIFONCTIONNELS

  摘要：

  公开号：

  WO2011133039A3
• 作为产物：
  描述：

  2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethyl (4-nitrophenyl) carbonate 、 炔丙胺 以 四氢呋喃 为溶剂， 以68 %的产率得到2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethyl prop-2-yn-1-ylcarbamate
  参考文献：
  名称：

  [EN] CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY
  [FR] CONJUGUÉS COMPRENANT DES PHOSPHOANTIGÈNES ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES

  摘要：

  The present invention relates to novel conjugates comprising a targeting moiety linked to a phosphoantigen moiety, and the use thereof in the treatment of diseases, such as cancer, infectious diseases and autoimmune diseases, optionally in combination with other therapeutic agents. A targeting moiety may be an antibody, or binding fragment thereof. The phosphoantigen may be a prodrug. The invention further relates to linker-drug compounds comprising a phosphoantigen moiety, for use in the manufacture of conjugates, and pharmaceutical compositions comprising said immunoconjugates.

  公开号：

  WO2023275025A1

文献信息

• Water-Soluble CC-1065 Analogs and Their Conjugates
  申请人：Beusker Patrick Henry

  公开号：US20090318668A1

  公开（公告）日：2009-12-24

  This invention relates to novel analogs of the DNA-binding alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

  这项发明涉及DNA结合烷基化剂CC-1065的新型类似物及其结合物。此外，该发明涉及用于制备上述剂和它们的结合物的中间体。这些结合物设计为在一个或多个激活步骤之后以及/或由结合物控制的速率和时间跨度下释放它们的（多种）荷载，以便选择性地传递和/或可控地释放一个或多个所述的DNA烷基化剂。这些剂、结合物和中间体可用于治疗以不良（细胞）增殖为特征的疾病。例如，这项发明的剂和结合物可用于治疗肿瘤。
• WO2007/89149
  申请人：——

  公开号：——

  公开（公告）日：——
• WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES
  申请人：Syntarga B.V.

  公开号：EP1994000B1

  公开（公告）日：2017-08-23
• US8940784B2
  申请人：——

  公开号：US8940784B2

  公开（公告）日：2015-01-27
• NOVEL LINKER DRUGS COMPRISING PHOSPHOANTIGENS, NOVEL CONJUGATES AND THEIR USE IN THERAPY
  申请人：[en]BYONDIS B.V.

  公开号：WO2024133374A1

  公开（公告）日：2024-06-27

  The present invention relates to novel linker drug compounds based on specific phosphoantigens (pAg) with the general structure reflected in formula (I), wherein L represents a linking moiety (linker) and, W1, W2, X1-5, x, m, n and R1-4are as defined in the specification. Further provided are conjugates comprising a targeting moiety, preferably a tumor-targeting antibody or antigen binding fragment thereof, covalently linked to a linker drug compound according to the invention. Such conjugates can be used, for example, in the treatment of diseases such as cancer, infection, or autoimmune disease.